

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Teprotumumab for treating thyroid eye disease [ID6432]

Final Stakeholder List

Provisional Consultees	Provisional Commentators (no right to
Fiovisional Consultees	submit or appeal)
	, and the spirit of
Company	General
Amgen Limited (teprotumumab)	All Wales Therapeutics and Toxicology
	Centre
Patient/carer groups	Allied Health Professionals Federation
British Thyroid Foundation	Board of Community Health Councils in
Changing Faces	Wales
Eyecare Trust	British National Formulary
Fight for Sight	Care Quality Commission
Immunodeficiency UK	Department of Health, Social Services And Bubble Sefety for North and Included
Macular Society	and Public Safety for Northern Ireland
National Federation of the Blind of the	Healthcare Improvement Scotland Medicines and Healthcare products
UK	Medicines and Healthcare products Populatory Agency
 OBAC (Organisation of Blind African Caribbeans) 	Regulatory AgencyNational Association of Primary Care
 Royal National Institute of Blind 	National Pharmacy Association
People	NHS Confederation
SeeAbility	Scottish Medicines Consortium
• Sense	Wales Council for the Blind
South Asian Health Foundation	Welsh Endocrine and Diabetes Society
Specialised Healthcare Alliance	Welsh Government
Thyroid Eye Disease Charitable Trust	Welsh Health Specialised Services
(TEDct)	Committee
Thyroid Trust	
Thomas Pocklington Trust	Comparator companies
	None
Healthcare professional groups	
Association of Optometrists	Relevant research groups
British and Irish Orthoptic Society	Cochrane Eyes and Vision Group
British Geriatrics Society British Geriatric Society Control of the Contro	Cochrane UK
British Oculoplastic Surgical Society British Or leth aloris Analysis Analysis	Eye Hope Conomics England
British Ophthalmic Anaesthesia Seciety (BOAS)	Genomics England Institute of Ophthalmalagy, University
Society (BOAS) - British Society for Immunology	 Institute of Ophthalmology, University College London
British Society for ImmunologyBritish Thyroid Association	MRC Clinical Trials Unit
British Thyroid AssociationCollege of Optometrists	National Eye Research Centre
Optical Confederation	National Institute for Health Research
 Royal College of General Practitioners 	Tradicial modulo for floater recodion
- Royal College of College i Tactitioners	

Final stakeholder list for the evaluation of teprotumumab for treating thyroid eye disease [ID6432] Issue date: October 2024



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
 Royal College of Nursing Royal College of Ophthalmologists Royal College of Pathologists Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine Society for Endocrinology UK Clinical Pharmacy Association 	 Associated Public Health groups Public Health Wales UK Health Security Agency
Others Department of Health and Social Care NHS England	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:


Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).



Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.